Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point [Yahoo! Finance]
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: Yahoo! Finance
The reported quarterly sales of $708.66 million missed the consensus estimate of $717.66 million Screening revenue was $545 million, an increase of 15%, and Precision Oncology's revenue was $164 million, an increase of 5% on a reported and core revenue basis. Also Read: FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test “While we have made progress, our execution during the third quarter and updated outlook for the full year don't reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong,” said Kevin Conroy, chairman and CEO. Guidance : Exact Sciences cuts its 2024 revenue guidance from $2.81 billion-$2.85 billion to $2.73 billion-$2.75 billion compared to the consensus of $2.832 billion. The guidance includes a Screening sales forecast of $2.08 billion—$2.095 billion, compared to previous guidance of $2.155 billion—$2.175 billion. Precision Oncology sales are expected to be $650 million- $655 mill
Show less
Read more
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- Exact Sciences Co. (NASDAQ: EXAS) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript) [Seeking Alpha]Seeking Alpha
- EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test [Yahoo! Finance]Yahoo! Finance
- Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community [Yahoo! Finance]Yahoo! Finance
EXAS
Earnings
- 11/5/24 - Miss
EXAS
Sec Filings
- 11/13/24 - Form SC
- 11/13/24 - Form 4
- 11/8/24 - Form SC
- EXAS's page on the SEC website